IndiaTickerCertificate under SEBI (Depositories and Participants) Regulations, 2018 - Lincoln Pharmaceuticals LimitedNSE · exchange filing · pdf
Source filing Company dossier
Lincoln Pharmaceuticals
NSE:LINCOLN · ISIN INE405C01035
- Close
- Unavailable Date unavailable
- Daily change
- N/A Exchange close
- Evidence state
- Building 0/0 checks
Lincoln Pharmaceuticals
Filings
Preserved evidence
40 recent eventsPrimary-source filing timeline
Lincoln Pharmaceuticals Ltd - 531633 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018BSE · exchange filing · pdf
Source filing Trading Window - Lincoln Pharmaceuticals LimitedNSE · exchange filing · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Closure of Trading WindowBSE · exchange filing · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Newspaper PublicationBSE · financial results · pdf
Source filing Copy of Newspaper Publication - Lincoln Pharmaceuticals LimitedNSE · financial results · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Audited Financial Results For The Quarter And Year Ended 31St March, 2026BSE · financial results · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results For The Quarter And Year Ended 31St March, 2026.BSE · financial results · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Corporate Action-Board approves DividendBSE · corporate action · pdf
Source filing Dividend - Lincoln Pharmaceuticals LimitedNSE · exchange filing · pdf
Source filing Outcome of Board Meeting - Lincoln Pharmaceuticals LimitedNSE · financial results · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Board Meeting Intimation for Consideration Of Audited (Standalone & Consolidated) Financial Results Of The Company For The Quarter And Year Ended On March 31, 2026.BSE · financial results · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Corporate Action-Board to consider DividendBSE · financial results · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Compliances-Reg.24(A)-Annual Secretarial ComplianceBSE · exchange filing · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Newspaper PublicationBSE · exchange filing · pdf
Source filing Copy of Newspaper Publication - Lincoln Pharmaceuticals LimitedNSE · exchange filing · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2BSE · exchange filing · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure ABSE · exchange filing · pdf
Source filing Disclosure under SEBI Takeover Regulations - Lincoln Pharmaceuticals LimitedNSE · exchange filing · pdf
Source filing Reply to Clarification- Financial results - Lincoln Pharmaceuticals LimitedNSE · financial results · pdf
Source filing Disclosure under SEBI Takeover Regulations - Lincoln Pharmaceuticals LimitedNSE · exchange filing · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018BSE · exchange filing · pdf
Source filing Certificate under SEBI (Depositories and Participants) Regulations, 2018 - Lincoln Pharmaceuticals LimitedNSE · exchange filing · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Closure of Trading WindowBSE · exchange filing · pdf
Source filing Trading Window - Lincoln Pharmaceuticals LimitedNSE · exchange filing · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptBSE · conference call · pdf
Source filing Analysts/Institutional Investor Meet/Con. Call Updates - Lincoln Pharmaceuticals LimitedNSE · conference call · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeBSE · exchange filing · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome — recordingBSE · conference call recording · audio
Source filing Analysts/Institutional Investor Meet/Con. Call Updates - Lincoln Pharmaceuticals LimitedNSE · conference call · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationBSE · conference call · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Newspaper PublicationBSE · financial results · pdf
Source filing Analysts/Institutional Investor Meet/Con. Call Updates - Lincoln Pharmaceuticals LimitedNSE · conference call · pdf
Source filing Copy of Newspaper Publication - Lincoln Pharmaceuticals LimitedNSE · exchange filing · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2025BSE · financial results · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Board Meeting Outcome for OUTCOME OF BOARD MEETINGBSE · exchange filing · pdf
Source filing Outcome of Board Meeting - Lincoln Pharmaceuticals LimitedNSE · financial results · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Third Quarter And Nine Months Ended 31St December, 2025.BSE · financial results · pdf
Source filing Lincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Credit RatingBSE · credit rating · pdf
Source filing Credit Rating - Lincoln Pharmaceuticals LimitedNSE · credit rating · pdf
Source filing